ValuEngine upgraded shares of Hill-Rom Holdings Inc (NYSE:HRC) from a hold rating to a buy rating in a research note released on Thursday morning.
A number of other brokerages have also weighed in on HRC. KeyCorp restated a buy rating and set a $89.00 price objective (up previously from $82.00) on shares of Hill-Rom Holdings in a research report on Sunday, November 5th. Zacks Investment Research upgraded Hill-Rom Holdings from a hold rating to a buy rating and set a $90.00 price objective on the stock in a research report on Friday, October 27th. Needham & Company LLC reduced their price objective on Hill-Rom Holdings from $93.00 to $90.00 and set a buy rating on the stock in a research report on Monday, November 6th. Stifel Nicolaus restated a buy rating and set a $84.00 price objective on shares of Hill-Rom Holdings in a research report on Sunday, July 30th. Finally, BidaskClub upgraded Hill-Rom Holdings from a sell rating to a hold rating in a research report on Sunday, August 6th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $88.57.
Hill-Rom Holdings (HRC) opened at $81.91 on Thursday. Hill-Rom Holdings has a 52 week low of $52.58 and a 52 week high of $84.65. The company has a quick ratio of 1.34, a current ratio of 1.77 and a debt-to-equity ratio of 1.55. The stock has a market capitalization of $5,391.40, a price-to-earnings ratio of 21.22, a PEG ratio of 1.74 and a beta of 1.19.
Hill-Rom Holdings (NYSE:HRC) last issued its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.05. Hill-Rom Holdings had a return on equity of 20.27% and a net margin of 4.87%. The company had revenue of $738.30 million for the quarter, compared to analyst estimates of $731.10 million. During the same quarter last year, the company posted $1.18 EPS. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. sell-side analysts expect that Hill-Rom Holdings will post 4.26 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/11/20/hill-rom-holdings-inc-hrc-upgraded-to-buy-at-valuengine.html.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be given a dividend of $0.18 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.72 dividend on an annualized basis and a yield of 0.88%. Hill-Rom Holdings’s dividend payout ratio is currently 36.18%.
In other news, SVP Andreas G. Frank sold 6,870 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $77.48, for a total value of $532,287.60. Following the transaction, the senior vice president now directly owns 16,701 shares of the company’s stock, valued at approximately $1,293,993.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Andreas G. Frank sold 3,940 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $77.84, for a total value of $306,689.60. Following the completion of the transaction, the senior vice president now directly owns 16,701 shares in the company, valued at $1,300,005.84. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.
Several large investors have recently made changes to their positions in HRC. Seven Eight Capital LP acquired a new position in shares of Hill-Rom Holdings in the 2nd quarter valued at about $127,000. Acrospire Investment Management LLC lifted its stake in shares of Hill-Rom Holdings by 43.4% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock valued at $158,000 after purchasing an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Hill-Rom Holdings by 10.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after purchasing an additional 204 shares during the period. Citigroup Inc. lifted its stake in shares of Hill-Rom Holdings by 21.1% in the 2nd quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after purchasing an additional 433 shares during the period. Finally, DekaBank Deutsche Girozentrale lifted its stake in shares of Hill-Rom Holdings by 101.0% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock valued at $204,000 after purchasing an additional 1,367 shares during the period. 80.37% of the stock is currently owned by institutional investors.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.